Kiniksa Pharmaceuticals International (KNSA) Competitors $35.42 -0.50 (-1.39%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$35.54 +0.13 (+0.35%) As of 09/19/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, and LEGNShould you be buying Kiniksa Pharmaceuticals International stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals International include QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals International vs. Its Competitors QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Qiagen (NYSE:QGEN) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability. Is QGEN or KNSA more profitable? Qiagen has a net margin of 18.30% compared to Kiniksa Pharmaceuticals International's net margin of 0.90%. Qiagen's return on equity of 14.77% beat Kiniksa Pharmaceuticals International's return on equity.Company Net Margins Return on Equity Return on Assets Qiagen18.30% 14.77% 8.87% Kiniksa Pharmaceuticals International 0.90%1.05%0.80% Which has more volatility and risk, QGEN or KNSA? Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Do institutionals & insiders hold more shares of QGEN or KNSA? 70.0% of Qiagen shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, QGEN or KNSA? Qiagen has higher revenue and earnings than Kiniksa Pharmaceuticals International. Qiagen is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B5.17$83.59M$1.6927.21Kiniksa Pharmaceuticals International$423.24M6.20-$43.19M$0.04885.50 Does the media favor QGEN or KNSA? In the previous week, Qiagen had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 8 mentions for Qiagen and 7 mentions for Kiniksa Pharmaceuticals International. Qiagen's average media sentiment score of 1.41 beat Kiniksa Pharmaceuticals International's score of 1.10 indicating that Qiagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiniksa Pharmaceuticals International 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate QGEN or KNSA? Qiagen currently has a consensus target price of $49.69, indicating a potential upside of 8.06%. Kiniksa Pharmaceuticals International has a consensus target price of $41.17, indicating a potential upside of 16.22%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryQiagen beats Kiniksa Pharmaceuticals International on 10 of the 16 factors compared between the two stocks. Get Kiniksa Pharmaceuticals International News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa Pharmaceuticals InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.66B$3.15B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio885.7221.0580.5826.78Price / Sales6.20448.41534.22123.54Price / CashN/A46.6037.9961.55Price / Book5.379.6615.776.40Net Income-$43.19M-$53.22M$3.30B$271.80M7 Day Performance-4.53%3.11%5.36%3.48%1 Month Performance6.65%7.56%8.10%9.90%1 Year Performance38.14%11.15%81.36%28.44% Kiniksa Pharmaceuticals International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals International2.6991 of 5 stars$35.42-1.4%$41.17+16.2%+34.9%$2.66B$423.24M885.72220Positive NewsInsider TradeShort Interest ↑QGENQIAGEN4.4567 of 5 stars$47.62+0.1%$49.69+4.4%+3.7%$10.57B$1.98B28.135,765BBIOBridgeBio Pharma4.3264 of 5 stars$54.29+1.7%$63.35+16.7%+95.2%$10.20B$221.90M-13.27400MRNAModerna4.473 of 5 stars$24.83-1.2%$42.88+72.7%-62.9%$9.78B$3.24B-3.305,800VRNAVerona Pharma PLC American Depositary Share2.0919 of 5 stars$106.300.0%$109.00+2.5%+260.6%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.7998 of 5 stars$19.02+3.2%$17.33-8.9%+27.3%$9.16B$4.44B22.129,000ROIVRoivant Sciences3.4472 of 5 stars$12.91-0.1%$16.38+26.8%+26.2%$8.82B$29.05M-18.44860Trending NewsAnalyst ForecastAnalyst RevisionRVMDRevolution Medicines4.2544 of 5 stars$41.06+1.4%$72.00+75.4%-5.7%$7.57B$11.58M-9.12250Trending NewsInsider TradeGRFSGrifols3.8383 of 5 stars$10.11-0.2%$10.30+1.9%+7.3%$6.96B$7.81B8.6423,822RYTMRhythm Pharmaceuticals3.2637 of 5 stars$99.77-2.3%$101.57+1.8%+76.1%$6.78B$130.13M-33.15140Positive NewsLEGNLegend Biotech3.1629 of 5 stars$34.62-4.0%$74.22+114.4%-33.1%$6.66B$627.24M-39.342,609Positive News Related Companies and Tools Related Companies QIAGEN Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Elanco Animal Health Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Legend Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNSA Stock Alerts